Startup profile · funding coverage
Century Health funding, valuation and investors
AI platform structuring real-world clinical data for pharma R&D and outcomes research.
Keep track of Century Health
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
$5M · May 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$5M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · New York, New York
Investors in latest funding
Lead: Origin Ventures
Other: 2048 Ventures , InnovateHealth Ventures , 25madison , Next Play Ventures , Alumni Ventures
Overview
Century Health applies AI to real-world clinical data — charts, notes, and specialty provider records — so life sciences teams run drug development, market access, and outcomes research on structured datasets. The NYC company raised a $5M oversubscribed seed in May 2026 led by Origin Ventures. Its CHARM model reported 97% accuracy vs. clinical expert judgment. Investors include 2048 Ventures, InnovateHealth, 25madison, Next Play, and Alumni Ventures, plus angels such as Citeline founder Zorba Lieberman.
Why Century Health is interesting
Pharma funds validated abstraction accuracy, not chat demos. CHARM hit 97% vs. clinician gold sets in company benchmarks — the eval buyers require before production.
Product & use cases
AI abstraction and structuring of clinical data from EHR notes, charts, and specialty datasets for pharma analytics and real-world evidence workflows.
- Clinical data abstraction for RWE studies
- Structuring specialty provider data for market access
- Accelerating outcomes research without manual chart review
Key facts
- Seed (May 2026): $5M led by Origin; 2048 Ventures participated (PR Newswire)
- CHARM: 97% accuracy vs. clinical experts per company benchmarks
- NYC healthtech; pharma R&D and market access focus
- Angels include Citeline founder Zorba Lieberman
Funding history (newest first)
Seed
2026-05 $5M- Origin Ventures (lead)
- 2048 Ventures (participant)
- InnovateHealth Ventures (participant)
- 25madison (participant)
- Next Play Ventures (participant)
- Alumni Ventures (participant)
Investors in our directory
Funds linked from Century Health's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Validated clinical abstraction accuracy on clinician-labeled gold sets — required for regulated life-sciences procurement.
Clinical abstraction incumbents own data networks; accuracy on specialty workflows remains hard. Century wins on eval rigor and speed; risk is bundling into broader RWE platforms.
-
Flatiron Health incumbent
Roche-owned oncology RWE; Century targets broader abstraction.
-
Truveta adjacent
Health-system data consortium vs. AI abstraction layer.
-
Tempus adjacent
Clinical/molecular data platform at scale.
Notable stories
- Leads with clinician gold-set evals — pattern winning healthtech seed in 2026.
- Oversubscribed seed for clinical data infrastructure, not wellness wrappers.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Century Health's financing or category context.
FAQs about Century Health
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.